Sarepta Therapeutics Inc (NASDAQ: SRPT) has a higher price-to-earnings ratio of 19.61x compared to its average ratio, The 36-month beta value for SRPT is at 0.77. Analysts have varying views on the stock, with 14 analysts rating it as a “buy,” 7 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for SRPT is 92.29M, and currently, shorts hold a 7.18% of that float. The average trading volume for SRPT on May 07, 2025 was 2.03M shares.
SRPT) stock’s latest price update
The stock of Sarepta Therapeutics Inc (NASDAQ: SRPT) has decreased by -26.56 when compared to last closing price of 63.66.Despite this, the company has seen a loss of -23.17% in its stock price over the last five trading days. zacks.com reported 2025-05-06 that The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SRPT’s Market Performance
SRPT’s stock has fallen by -23.17% in the past week, with a monthly drop of -14.11% and a quarterly drop of -59.02%. The volatility ratio for the week is 10.54% while the volatility levels for the last 30 days are 7.80% for Sarepta Therapeutics Inc The simple moving average for the last 20 days is -18.04% for SRPT’s stock, with a simple moving average of -58.40% for the last 200 days.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with Wells Fargo repeating the rating for SRPT by listing it as a “Overweight.” The predicted price for SRPT in the upcoming period, according to Wells Fargo is $115 based on the research report published on April 11, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $75. The rating they have provided for SRPT stocks is “Neutral” according to the report published on April 02nd, 2025.
RBC Capital Mkts gave a rating of “Sector Perform” to SRPT, setting the target price at $87 in the report published on March 31st of the current year.
SRPT Trading at -36.85% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.02% of loss for the given period.
Volatility was left at 7.80%, however, over the last 30 days, the volatility rate increased by 10.54%, as shares sank -10.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.71% lower at present.
During the last 5 trading sessions, SRPT fell by -23.17%, which changed the moving average for the period of 200-days by -67.49% in comparison to the 20-day moving average, which settled at $57.04. In addition, Sarepta Therapeutics Inc saw -61.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Nicaise Claude, who sale 2,491 shares at the price of $99.64 back on Mar 12 ’25. After this action, Nicaise Claude now owns 27,812 shares of Sarepta Therapeutics Inc, valued at $248,203 using the latest closing price.
Nicaise Claude, the Director of Sarepta Therapeutics Inc, proposed sale 2,491 shares at $99.65 during a trade that took place back on Mar 12 ’25, which means that Nicaise Claude is holding shares at $248,226 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.83 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value 19.71, with 6.51 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.15. The debt to equity ratio resting at 0.88. The interest coverage ratio of the stock is 11.86.
Currently, EBITDA for the company is 333.06 million with net debt to EBITDA at 0.78. When we switch over and look at the enterprise to sales, we see a ratio of 2.54. The receivables turnover for the company is 2.93for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.20.
Conclusion
In conclusion, Sarepta Therapeutics Inc (SRPT) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
